Edition:
United States

People: Sarepta Therapeutics Inc (SRPT.O)

SRPT.O on Nasdaq

101.50USD
21 Aug 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$101.50
Open
$101.71
Day's High
$103.37
Day's Low
$99.64
Volume
2,138,845
Avg. Vol
1,304,866
52-wk High
$165.87
52-wk Low
$95.21

Behrens, M. Kathleen 

Dr. M. Kathleen Behrens, Ph.D., is Independent Chairwoman of the Board of the Company. Dr. Behrens has served as a member of our Board since March 2009 and as Chairwoman of the Board since April 2015. She also serves as member of our research and development committee and as a member of and chair of our audit committee. Dr. Behrens served as a member of the President’s Council of Advisors on Science and Technology (PCAST) from 2001 to early 2009 and as Chairwoman of PCAST’s Subcommittee on Personalized Medicine. She has served as a public-market biotechnology securities analyst as well as a venture capitalist focusing on healthcare, technology and related investments. Dr. Behrens was instrumental in the founding of several biotechnology companies, including Protein Design Labs, Inc. and COR Therapeutics, Inc. She worked for Robertson Stephens & Co. from 1983 through 1996, serving as a General Partner and Managing Director. Dr. Behrens continued in her capacity as a General Partner for selected venture funds for RS Investments, an investment management and research firm, from 1996 through December 2009, after management led a buyout of that firm from Bank of America. While Dr. Behrens worked at RS Investments, from 1996 to 2002, she served as a Managing Director at the firm and, from 2003 to December 2009, she served as a consultant to the firm. From 1997 to 2005, she was a director of the Board on Science, Technology and Economic Policy for the National Research Council, and from 1993 to 2000 she was a Director, President and Chairwoman of the National Venture Capital Association. Since December 2009, Dr. Behrens has worked as an independent life sciences consultant and investor. Dr. Behrens was a director of Amylin Pharmaceuticals, Inc. from June 2009 until Amylin’s sale in August 2012 to Bristol-Myers Squibb Company. Dr. Behrens also served as the President and Chief Executive Officer of KEW Group Inc., a private oncology services company.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Awards, USD 244,216
Long-Term Incentive Plans, USD --
All Other, USD 257,936
Fiscal Year Total, USD 502,152

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

M. Kathleen Behrens

502,152

Douglas Ingram

1,433,870

Sandesh Mahatme

4,219,080

David Howton

3,129,380

Alexander Cumbo

3,115,160

Gilmore O'Neill

6,449,180
As Of  30 Dec 2018